Positive Bioscience will offer Biodesix's liquid biopsy tests for non-small cell lung cancer in India.
According to a new study, the company returns results for more than 90 percent of its GeneStrat tests within 72 hours and aims to bring that down to 48 hours.
The test, which the company plans to launch later this year, will use MALDI-based proteomics to assess patients' likelihood of responding to immunotherapies.
Progenetics will distribute GeneStrat and Veristrat liquid biopsy tests in Israel, making Biodesix's tests available in the Middle East for the first time.
The deal gives the firm access to Bioyong's network of hospital-installed mass specs on which it hopes to place assays including its Veristrat lung cancer test.
Studies presented at the recent SITC annual meeting indicate the company's MALDI-based proteomic tests could help guide checkpoint inhibitor treatment.
The company said Humana, Medical Mutual of Ohio, and PreferredOne will now cover the non-small cell lung cancer test for their 11.5 million members.
Recently presented studies support the utility of Genestrat and Veristrat for detecting actionable mutations and guiding therapy in drug-resistant lung cancer patients.
Clinical lab supply firm Streck will exclusively supply Biodesix with DNA and RNA tubes, including its lines of blood collection tubes.
Horizon BCBS of New Jersey, which covers 3.8 million people in that state, began covering the test for patients with non-small cell lung cancer on May 10, 2016.
The Wall Street Journal looks into FamilyTreeDNA's handling of genetic genealogy searches by law enforcement.
In a point-counterpoint in the Boston Globe, researchers discuss the potential of gene editing to prevent Lyme disease, but also the pitfalls of doing so.
MIT's Technology Review reports that researchers hope to develop a CRISPR-based pain therapy.
In Science this week: atlas of malaria parasites' gene expression across their life cycles, and more.